case_images: PMC5682071_01
case_images: Magnetic resonance imaging findings at the initial visit. (a) T1-weighted fat suppression gadolinium-enhanced image (axial view). (b) T1-weighted fat suppression gadolinium-enhanced image (sagittal view). This MRI showed a large lobulated lesion with strong enhancement. The tumor was located at the abdominal wall, bulging to the lumbar spine.
case_images: CRIONM2017-3738562.001.jpg
case_images: PMC5682071_01_CRIONM2017-3738562.001.jpg
case_images: fig1
case_images: T1- and T2-weighted images, suggesting flow void. The tumor was located at the abdominal wall, bulging to the lumbar spine (Figure 1).
case_images: Enhanced computed tomography findings at the initial visit. CT revealed marked dot-like enhancement at the arterial phase, suggesting abundant vascular formation.
case_images: CRIONM2017-3738562.002.jpg
case_images: PMC5682071_01_CRIONM2017-3738562.002.jpg
case_images: fig2
case_images: Enhanced CT revealed marked dot-like enhancement at the arterial phase, suggesting abundant vascular formation (Figure 2).
case_images: Magnetic resonance imaging findings (T1-weighted fat suppression gadolinium-enhanced image). (a) After four courses of IFM/DXR. (b) After 31 months of pazopanib administration. It was classified as no change by the RECIST criteria; however, slight tumor reduction and a decrease of enhancement were observed after 31 months of pazopanib administration.
case_images: CRIONM2017-3738562.003.jpg
case_images: PMC5682071_01_CRIONM2017-3738562.003.jpg
case_images: fig3
case_images: In comparison with the MRI obtained after the initial chemotherapy regimen, the response was defined as stable disease by the RECIST criteria; however, slight tumor reduction and a decrease of enhancement were observed after 31 months of pazopanib administration (Figures 3 and 3).
case_images: Computed tomography findings. (a) After four courses of IFM/DXR. (b) After 31 months of pazopanib administration. It was classified as no change by the RECIST criteria; however, slight tumor reduction was observed after 31 months of pazopanib administration.
case_images: CRIONM2017-3738562.004.jpg
case_images: PMC5682071_01_CRIONM2017-3738562.004.jpg
case_images: fig4
case_images: Chest CT also showed slight reduction of the lung metastases after 34 months of pazopanib administration (Figures 4 and 4).
case_images: Head magnetic resonance imaging findings (T1-weighted fat suppression gadolinium-enhanced image) after 35 months of pazopanib administration. This MRI showed brain metastases with surrounding edema and a midline shift.
case_images: CRIONM2017-3738562.005.jpg
case_images: PMC5682071_01_CRIONM2017-3738562.005.jpg
case_images: fig5
case_images: At this time, brain CT and MRI revealed multiple brain metastases, with surrounding edema and a midline shift (Figure 5).
case_images: Magnetic resonance imaging findings (T1-weighted fat suppression gadolinium-enhanced image) after a drug holiday for six weeks. Tumor regrowth with increased enhancement was observed.
case_images: CRIONM2017-3738562.006.jpg
case_images: PMC5682071_01_CRIONM2017-3738562.006.jpg
case_images: fig6
case_images: A drug holiday for six weeks was needed, after which tumor regrowth was observed (Figure 6).